Mechanism-Based Inactivation of Human Cytochrome P450 Enzymes and the Prediction of Drug-Drug Interactions
Top Cited Papers
Open Access
- 8 November 2006
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 35 (2), 246-255
- https://doi.org/10.1124/dmd.106.012633
Abstract
The ability to use vitro inactivation kinetic parameters in scaling to in vivo drug-drug interactions (DDIs) for mechanism-based inactivators of human cytochrome P450 (P450) enzymes was examined using eight human P450-selective marker activities in pooled human liver microsomes. These data were combined with other parameters (systemic Cmax, estimated hepatic inlet Cmax, fraction unbound, in vivo P450 enzyme degradation rate constants estimated from clinical pharmacokinetic data, and fraction of the affected drug cleared by the inhibited enzyme) to predict increases in exposure to drugs, and the predictions were compared with in vivo DDIs gathered from clinical studies reported in the scientific literature. In general, the use of unbound systemic Cmax as the inactivator concentration in vivo yielded the most accurate predictions of DDI with a mean -fold error of 1.64. Abbreviated in vitro approaches to identifying mechanism-based inactivators were developed. Testing potential inactivators at a single concentration (IC25) in a 30-min preincubation with human liver microsomes in the absence and presence of NADPH followed by assessment of P450 marker activities readily identified those compounds known to be mechanism-based inactivators and represents an approach that can be used with greater throughput. Measurement of decreases in IC50 occurring with a 30-min preincubation with liver microsomes and NADPH was also useful in identifying mechanism-based inactivators, and the IC50 measured after such a preincubation was highly correlated with the kinact/KI ratio measured after a full characterization of inactivation. Overall, these findings support the conclusion that P450 in vitro inactivation data are valuable in predicting clinical DDIs that can occur via this mechanism.Keywords
This publication has 45 references indexed in Scilit:
- PREDICTION OF TIME-DEPENDENT CYP3A4 DRUG-DRUG INTERACTIONS: IMPACT OF ENZYME DEGRADATION, PARALLEL ELIMINATION PATHWAYS, AND INTESTINAL INHIBITIONDrug Metabolism and Disposition, 2005
- Prediction of in vivo drug–drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constantBritish Journal of Clinical Pharmacology, 2005
- Mechanism-Based Inactivation of CYP3A by HIV Protease InhibitorsThe Journal of pharmacology and experimental therapeutics, 2004
- Time response of cytochrome P450 1A2 activity on cessation of heavy smoking*1Clinical Pharmacology & Therapeutics, 2004
- Lack of Pharmacologic Interaction Between Paroxetine and Alprazolam at Steady State in Healthy VolunteersJournal of Clinical Psychopharmacology, 2004
- Apparent Mechanism-based Inhibition of Human CYP2D6 in Vitro by Paroxetine: Comparison with Fluoxetine and QuinidineDrug Metabolism and Disposition, 2003
- Desipramine Pharmacokinetics When Coadministered With Paroxetine or Sertraline in Extensive MetabolizersJournal of Clinical Psychopharmacology, 1997
- Differential induction of prehepatic and hepatic metabolism of verapamil by rifampinJournal of Hepatology, 1996
- Dose of midazolam should be reduced during diltiazem and verapamil treatments.British Journal of Clinical Pharmacology, 1994
- Ticlopidine-theophylline interactionClinical Pharmacology & Therapeutics, 1987